Mga Batayang Estadistika
| LEI | 549300ZLRH6GSBOHFZ59 |
| CIK | 1536196 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Can-Fite BioPharma Ltd. - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 28, 2025 |
Can-Fite Reports H1 2025 Financial Results and Clinical Update Exhibit 99.3 Can-Fite Reports H1 2025 Financial Results and Clinical Update Ramat Gan, Israel, August 28, 2025 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced financial results and clinical updates for H1, 2025. Clinical & Development Mile |
|
| August 28, 2025 |
Exhibit 99.2 CAN-FITE BIOPHARMA LTD AND ITS SUBSIDIARY. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2025 UNAUDITED IN U.S. DOLLARS IN THOUSANDS INDEX Page Condensed Consolidated Balance Sheets 2 - 3 Condensed Consolidated Statements of Net Loss 4 Condensed Consolidated Statements of Changes in Shareholders’ Equity 5 Condensed Consolidated Statements of Cash Flows 6 - 7 Notes to Cond |
|
| August 28, 2025 |
As filed with the Securities and Exchange Commission on August 28, 2025 As filed with the Securities and Exchange Commission on August 28, 2025 Registration No. |
|
| August 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2025 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal |
|
| August 28, 2025 |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Exhibit 99.1 OPERATING AND FINANCIAL REVIEW AND PROSPECTS You should read the following selected financial data and discussion of our operating and financial condition and prospects in conjunction with the financial statements and the notes thereto included elsewhere in this 6-K and our Annual Report on Form 20-F for the year ended December 31, 2024 (the “Annual Report”). Our financial statements |
|
| August 28, 2025 |
As filed with the Securities and Exchange Commission on August 28, 2025 As filed with the Securities and Exchange Commission on August 28, 2025 Registration No. |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2025 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal e |
|
| July 30, 2025 |
Exhibit 99.1 Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone Primary endpoint is safety; Namodenoson continues to demonstrate a favorable safety profile Ramat Gan, Israel, July 30, 2025 (GLOBE NEWSWIRE) - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small m |
|
| July 29, 2025 |
Exhibit 4.1 WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES CAN-FITE BIOPHARMA LTD. Warrant No.: 2025– Initial Exercise Date: July 29, 2025 Issue Date: July 29, 2025 Number of American Depositary Shares: THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) i |
|
| July 29, 2025 |
Exhibit 4.2 PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES CAN-FITE BIOPHARMA LTD. Warrant No.: 2025– Initial Exercise Date: July 29, 2025 Issue Date: July 29, 2025 Number of American Depositary Shares: THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its as |
|
| July 29, 2025 |
Exhibit 4.3 PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES CAN-FITE BIOPHARMA LTD. Warrant No.: 2025– Initial Exercise Date: July 29, 2025 Issue Date: July 29, 2025 Number of American Depositary Shares: THIS PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, |
|
| July 29, 2025 |
PROSPECTUS Filed pursuant to Rule 424(b)(4) Registration No. 333-288890 Can-Fite BioPharma Ltd. Up to 1,250,000 American Depositary Shares Representing 375,000,000 Ordinary Shares and accompanying 2,500,000 Common Warrants to Purchase up to 2,500,000 American Depositary Shares Representing 750,000,000 Ordinary Shares Up to 7,083,333 Pre-Funded Warrants to Purchase up to 7,083,333 American Deposita |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2025 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal e |
|
| July 29, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 28, 2025, between Can-Fite BioPharma Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, s |
|
| July 28, 2025 |
Exhibit 99.1 Can-Fite Announces Up To $15.0 Million Public Offering $5.0 million upfront with up to an additional $10.0 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants RAMAT GAN, Israel, July 28, 2025 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a clinical-stage biotechnology company developing a pipeline |
|
| July 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2025 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal e |
|
| July 28, 2025 |
Exhibit 99.1 Breakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment for Vascular Dementia Ramat Gan, Israel, July 28, 2025 (GLOBE NEWSWIRE) - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced that |
|
| July 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2025 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal e |
|
| July 25, 2025 |
Exhibit 10.46 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2025, between Can-Fite BioPharma Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject |
|
| July 25, 2025 |
WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY CAN-FITE BIOPHARMA LTD. Exhibit 4.2 WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES CAN-FITE BIOPHARMA LTD. Warrant No.: 2025– Initial Exercise Date: , 2025 Issue Date: , 2025 Number of American Depositary Shares: THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, up |
|
| July 25, 2025 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form F-1 (Form Type) Can-Fite BioPharma Ltd. |
|
| July 25, 2025 |
As filed with the Securities and Exchange Commission on July 25, 2025. As filed with the Securities and Exchange Commission on July 25, 2025. Registration No. 333-288890 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Can-Fite BioPharma Ltd. (Exact name of registrant as specified in its charter) State of Israel 2834 Not Applicable (State or other jurisdiction o |
|
| July 25, 2025 |
Exhibit 4.4 PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES CAN-FITE BIOPHARMA LTD. Warrant No.: 2025– Initial Exercise Date: , 2025 Issue Date: , 2025 Number of American Depositary Shares: THIS PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assign |
|
| July 24, 2025 |
Can-Fite BioPharma Ltd. 26 Ben Gurion Street Ramat Gan 5257346 Israel Can-Fite BioPharma Ltd. 26 Ben Gurion Street Ramat Gan 5257346 Israel July 24, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Can-Fite BioPharma Ltd. (CIK 0001536196) Registration Statement No. 333-288890 on Form F-1 (the “Registration Statement”) Ladies and Gentlemen: Can-Fite BioPharma Ltd. (the “Registrant”) hereby r |
|
| July 24, 2025 |
July 24, 2025 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: Can-Fite BioPharma Ltd. Registration Statement on Form S-1 (Registration No. 333-288890) Concurrence in Acceleration Request Ladies and Gentlemen: H.C. Wainwright & Co., LLC (“Wainwright”), solely acting as placement agent on a best-efforts basis in an offering pursu |
|
| July 23, 2025 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form F-1 (Form Type) Can-Fite BioPharma Ltd. |
|
| July 23, 2025 |
WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY CAN-FITE BIOPHARMA LTD. Exhibit 4.2 WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES CAN-FITE BIOPHARMA LTD. Warrant No.: 2025– Initial Exercise Date: , 2025 Issue Date: , 2025 Number of American Depositary Shares: THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, up |
|
| July 23, 2025 |
Exhibit 10.46 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2025, between Can-Fite BioPharma Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject |
|
| July 23, 2025 |
As filed with the Securities and Exchange Commission on July 23, 2025. As filed with the Securities and Exchange Commission on July 23, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Can-Fite BioPharma Ltd. (Exact name of registrant as specified in its charter) State of Israel 2834 Not Applicable (State or other jurisdiction of incorporation or organi |
|
| July 23, 2025 |
Exhibit 4.4 PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES CAN-FITE BIOPHARMA LTD. Warrant No.: 2025– Initial Exercise Date: , 2025 Issue Date: , 2025 Number of American Depositary Shares: THIS PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assign |
|
| July 23, 2025 |
Exhibit 4.3 PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES CAN-FITE BIOPHARMA LTD. Warrant No.: 2025– Initial Exercise Date: , 2025 Issue Date: , 2025 Number of American Depositary Shares: THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Ho |
|
| July 9, 2025 |
As confidentially submitted to the Securities and Exchange Commission on July 9, 2025. |
|
| June 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2025 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal e |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2025 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal e |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2025 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal e |
|
| June 16, 2025 |
Exhibit 99.1 Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston Ramat Gan, Israel, June 16, 2025 (GLOBE NEWSWIRE) - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and infla |
|
| May 16, 2025 |
Exhibit 99.2 CAN-FITE BIOPHARMA LTD. PROXY FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 23, 2025 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. The undersigned hereby appoints Dr. Pnina Fishman, Chairman of the Board and Motti Farbstein, Chief Executive Officer and each of them, attorneys, agents and proxies of the undersigned, with full power of substitution to |
|
| May 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2025 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346, Israel (Address of principal e |
|
| May 16, 2025 |
Exhibit 99.3 YOUR VOTE IS IMPORTANT! PLEASE VOTE BY: 12:00 p.m. E.D.T. on June 16, 2025. Can - Fite BioPharma Ltd. Instructions to The Bank of New York, as Depositary (Must be received prior to 12:00 p.m. E.D.T. on June 16, 2025) The undersigned registered owner of American Depositary Shares hereby requests and instructs The Bank of New York, as Depositary, to endeavor, in so far as practicable, t |
|
| May 16, 2025 |
NOTICE OF 2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 23, 2025 Exhibit 99.1 NOTICE OF 2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 23, 2025 To the shareholders of Can-Fite BioPharma Ltd.: Notice is hereby given that the 2025 Annual General Meeting of Shareholders will be held on Monday, June 23, 2025, at 3:00 p.m. Israel time at our offices, 26 Ben Gurion Street, Ramat Gan 5257346 Israel. The agenda of the annual meeting will be as follows: |
|
| May 9, 2025 |
Can-Fite BioPharma Ltd. Up to $2,573,000 of American Depositary Shares Representing Ordinary Shares Filed pursuant to Rule 424(b)(5) Registration No. 333-274316 PROSPECTUS SUPPLEMENT (To prospectus dated September 12, 2023) Can-Fite BioPharma Ltd. Up to $2,573,000 of American Depositary Shares Representing Ordinary Shares This prospectus supplement amends and supplements the information in the prospectus, dated September 12, 2023, filed as a part of our registration statement on Form F-3 (File N |
|
| May 5, 2025 |
Exhibit 99.1 Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis Ramat Gan, Israel, May 05, 2025 (GLOBE NEWSWIRE) - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and infl |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2025 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal ex |
|
| April 17, 2025 |
Exhibit 99.1 Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite’s Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients Ramat Gan, Israel, April 17, 2025 (GLOBE NEWSWIRE) - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and infl |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of April 2025 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal |
|
| April 15, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 14, 2025, between Can-Fite BioPharma Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to th |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2025 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. ((Translation of registrant’s name into English) Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal executive |
|
| April 15, 2025 |
750,000,000 Ordinary Shares Represented by 2,500,000 American Depositary Shares PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus dated September 12, 2023) Registration No. |
|
| April 15, 2025 |
Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| April 14, 2025 |
Appendix A Declaration of confidentiality and non-use of inside information Exhibit 11.1 Can-Fite BioPharma Ltd., Administrative Enforcement Plan Policy for Restricting the Use of Inside Information for the Company Policy No. 005 1. Introduction 1.1 The Securities Law, 5728-1968 (hereinafter: “Securities Law”) imposes restrictions on the use of inside information held by a person and/or a corporation, the main restriction of which is the prohibition of carrying out transa |
|
| April 14, 2025 |
Exhibit 99.1 Can-Fite Reports 2024 Financial Results and Clinical Update Cancer-Free Survival of 8 Years in Liver Cancer Patient Treated with Namodenoson in Prior Phase II Study Ramat Gan, Israel, April 14, 2025 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory disea |
|
| April 14, 2025 |
Exhibit 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Can-Fite BioPharma Ltd. (the “Company”) hereby certifies to such officer’s knowledge that: (i) the accompanying Annua |
|
| April 14, 2025 |
As filed with the Securities and Exchange Commission on April 14, 2025 As filed with the Securities and Exchange Commission on April 14, 2025 Registration No. |
|
| April 14, 2025 |
Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships Exhibit 99.1 Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships Ramat Gan, Israel, April 14, 2025 (GLOBE NEWSWIRE) - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory diseases, today announced the completion of a comprehensive analysis of its curren |
|
| April 14, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the following Registration Statements: 1. Registration Statement (Form F-3 No. 333-236064) of Can-Fite BioPharma Ltd., 2. Registration Statement (Form F-3 No. 333-276000) of Can-Fite BioPharma Ltd., 3. Registration Statement (Form F-3 No. 333-274316) of Can-Fite BioPharma Ltd., 4. |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of April 2025 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of April 2025 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal |
|
| April 14, 2025 |
Can-fite Biopharma Ltd. (hereinafter: “the Company”) COMPENSATION POLICY TO OFFICERS Exhibit 4.10 Can-fite Biopharma Ltd. (hereinafter: “the Company”) COMPENSATION POLICY TO OFFICERS Date of approval of General Meeting: July 3, 2024 Date of last update: November 29, 2023 Contents Item Subject Page 1 Definitions 1 2 Object of the compensation policy and its implementation 1 3 Guiding principles for examining and determining the tenure and employment of Officers 2 4 Structure of the |
|
| April 14, 2025 |
Exhibit 12.1 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECURITIES EXCHANGE ACT OF 1934 RULES 13A-14(A) AND 15D-14(A), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Motti Farbstein, certify that: 1. I have reviewed this annual report on Form 20-F of Can-Fite BioPharma Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a mate |
|
| April 14, 2025 |
Exhibit 1.1 Articles of Association Pursuant to the Companies Law, 1999, of a Company Limited by Shares CAN FITE BIOPHARMA LTD. Clause Page 1 Interpretation 1 2 Company Name 2 3 Company Purposes 2 4 Company Intent 2 5 Authorised Share Capital 2 6 Shareholder Liability 2 7 Public Company 2 8 Shares 3 9 Share Certificate; Share Warrant 4 10 Call on Shares 5 11 Share Forfeiture and Mortgage 5 12 Shar |
|
| April 14, 2025 |
Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares Exhibit 99.1 Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares RAMAT GAN, Israel, April 14, 2025 (GLOBE NEWSWIRE) - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory diseases (“Can-Fite” or the “Company”), today announced that it has ent |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of April 2025 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal |
|
| April 14, 2025 |
DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Exhibit 2.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT General Can-Fite BioPharma Ltd. is currently authorized to issue 10,000,000,000 ordinary shares, no par value. NYSE American On November 19, 2013, our ADSs began trading on the NYSE American under the symbol “CANF.” Memorandum and Articles of Association Our number with the Israeli Registrar of Companies is 51202 |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of March 2025 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal |
|
| March 24, 2025 |
Exhibit 99.1 Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs Ramat Gan, Israel, March 24, 2025 (GLOBE NEWSWIRE) - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietar |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of March 2025 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal |
|
| March 20, 2025 |
Exhibit 99.1 Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market Can-Fite’s upfront and royalties on sales upon regulatory approval of Piclidenoson for veterinary use, is projected to be $325 million in the aggregate over the next decade assuming a 2029 launch Ramat Gan, Israel, March 20, 2025 (GLOBE NEWSWIR |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of March 2025 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal |
|
| March 19, 2025 |
Exhibit 99.1 Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson FDA & EMA approvals for rare genetic diseases are fast and require clinical studies with small number of patients Ramat Gan, Israel, March 19, 2025 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs t |
|
| March 18, 2025 |
Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient Exhibit 99.1 Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient Ramat Gan, Israel, March 18, 2025 (GLOBE NEWSWIRE) - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that it received a single FD |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of March 2025 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of March 2025 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal |
|
| March 3, 2025 |
Exhibit 99.1 Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits Unlike chemotherapy with its known toxicity towards normal body systems, Namodenoson provides protective effects Ramat Gan, Israel, March 03, 2025 (GLOBE NEWSWIRE) - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developin |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of February 2025 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of princip |
|
| February 18, 2025 |
Exhibit 99.1 Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite’s Namodenoson Liver cirrhosis treatment market is estimated to reach approximately $15 billion in the U.S. by 2030 Ramat Gan, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecul |
|
| February 5, 2025 |
6-K 1 ea0230008-6kcanfite.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of February 2025 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 |
|
| February 5, 2025 |
EX-99.1 2 ea023000801ex99-1canfite.htm PRESS RELEASE DATED FEBRUARY 5, 2025 Exhibit 99.1 Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025 Ramat Gan, Israel, Feb. 05, 2025 (GLOBE NEWSWIRE) - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address on |
|
| February 5, 2025 |
Exhibit 99.2 Small Molecules for Big Clinical Needs TM NYSE American:CANF February 2025 Forward Looking Statement This presentation may contain forward - looking statements, about Can - Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects . All statements in this comm |
|
| January 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of January 2025 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principa |
|
| January 27, 2025 |
Exhibit 99.1 US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug The Namodenoson oral drug is well positioned in the field of anti-obesity agents due to its activity and favorable safety profile Ramat Gan, Israel, Jan. 27, 2025 (GLOBE NEWSWIRE) - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary smal |
|
| December 30, 2024 |
Exhibit 99.1 Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson ● Can-Fite’s data will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium ● Can-Fite enrolls patients for its pivotal Phase III advanced liver cancer study Ramat Gan, Israel, Dec. 30, 2024 (GLOBE NEWSWIRE) - Can-Fite BioPharma Ltd. (NY |
|
| December 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of princip |
|
| December 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of princip |
|
| December 4, 2024 |
Exhibit 99.1 8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug RAMAT GAN, Israel, Dec. 04, 2024 (GLOBE NEWSWIRE) - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, announced today th |
|
| November 14, 2024 |
SC 13G/A 1 armistice-canf093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Can-Fite BioPharma Ltd. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 13471N300 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Che |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of princip |
|
| November 12, 2024 |
Exhibit 99.1 Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial Orphan Drug Designation has been granted lately by US FDA RAMAT GAN, Israel, Nov. 11, 2024 (GLOBE NEWSWIRE) - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflamm |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of princip |
|
| November 4, 2024 |
Exhibit 99.1 Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia Namodenoson is an oral drug with a proven favorable safety profile RAMAT GAN, Israel, Nov. 04, 2024 (GLOBE NEWSWIRE) - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases |
|
| October 18, 2024 |
Exhibit 99.1 Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson Data Reported by Can-Fite Veterinary Partner Vetbiolix who already exercised its option for a full license deal worth $325M Ramat Gan, Israel, Oct. 18, 2024 (GLOBE NEWSWIRE) - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of propr |
|
| October 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of October 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principa |
|
| October 9, 2024 |
FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer Exhibit 99.1 FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer RAMAT GAN, Israel, Oct. 09, 2024 (GLOBE NEWSWIRE) - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced the Company’s oncology drug candidate, Namo |
|
| October 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of October 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principa |
|
| September 24, 2024 |
6-K 1 ea0215472-6kcanfite.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 2 |
|
| September 24, 2024 |
EX-99.1 2 ea021547201ex99-1canfite.htm PRESS RELEASE DATED SEPTEMBER 24, 2024 Exhibit 99.1 Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis The agreement has been signed upon successful conclusion of a clinical study in dogs with osteoarthritis RAMAT GAN, Israel, Sept. 24, 2024 (GLOBE NEWSWIRE) |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of princi |
|
| September 16, 2024 |
Exhibit 99.1 Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health Study will aim to establish safety and clinical efficacy PETACH TIKVA, Israel, Sept. 16, 2024 (GLOBE NEWSWIRE) - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molec |
|
| September 6, 2024 |
Can-Fite BioPharma Ltd. 26 Ben Gurion Street Ramat Gan 5257346 Israel Can-Fite BioPharma Ltd. 26 Ben Gurion Street Ramat Gan 5257346 Israel September 6, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Can-Fite BioPharma Ltd. (CIK 0001536196) Registration Statement No. 333-281872 on Form F-3 (the “Registration Statement”) Ladies and Gentlemen: Can-Fite BioPharma Ltd. (the “Registrant”) here |
|
| September 6, 2024 |
1,774,285,800 Ordinary Shares represented by 5,914,286 American Depositary Shares PROSPECTUS Filed pursuant to Rule 424(b)(3) Registration No. 333-281872 1,774,285,800 Ordinary Shares represented by 5,914,286 American Depositary Shares This prospectus relates to the resale, by the selling shareholders identified in this prospectus, of up to an aggregate of up to 1,774,285,800 ordinary shares, no par value, of Can-Fite Biopharma Ltd., represented by 5,914,286 American Depository |
|
| August 30, 2024 |
As filed with the Securities and Exchange Commission on August 30, 2024 As filed with the Securities and Exchange Commission on August 30, 2024 Registration No. |
|
| August 30, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form F-3 (Form Type) Can-Fite BioPharma Ltd. |
|
| August 30, 2024 |
Up to $9,000,000 of American Depositary Shares Representing Ordinary Shares PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus dated September 12, 2023) Registration No. |
|
| August 30, 2024 |
As filed with the Securities and Exchange Commission on August 30, 2024 As filed with the Securities and Exchange Commission on August 30, 2024 Registration No. |
|
| August 30, 2024 |
AT THE MARKET OFFERING AGREEMENT Exhibit 10.1 AT THE MARKET OFFERING AGREEMENT August 30, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Can-Fite Biopharma Ltd., a corporation organized under the laws of the State of Israel (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, whe |
|
| August 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal |
|
| August 29, 2024 |
Exhibit 99.3 Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies RAMAT GAN, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results and |
|
| August 29, 2024 |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Exhibit 99.1 OPERATING AND FINANCIAL REVIEW AND PROSPECTS You should read the following selected financial data and discussion of our operating and financial condition and prospects in conjunction with the financial statements and the notes thereto included elsewhere in this 6-K and our Annual Report on Form 20-F for the year ended December 31, 2023 (the “Annual Report”). Our financial statements |
|
| August 29, 2024 |
Exhibit 99.2 CAN-FITE BIOPHARMA LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 UNAUDITED IN U.S. DOLLARS IN THOUSANDS INDEX Page Condensed Consolidated Balance Sheets 2 - 3 Condensed Consolidated Statements of Comprehensive Loss 4 Condensed Consolidated Statements of Changes in Equity 5 Condensed Consolidated Statements of Cash Flows 6 Notes to Condensed Consolidated Financia |
|
| August 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal |
|
| August 12, 2024 |
Exhibit 10.1 Can-Fite Biopharma Ltd. August 8, 2024 Holder of Warrants to Purchase Ordinary Shares Represented by American Depositary Shares Issued in January 2023 and November 2023 Re: Inducement Offer to Exercise Warrant to Purchase Ordinary Shares Represented by American Depositary Shares Issued in January 2023 and November 2023 Dear Holder: Can-Fite Biopharma Ltd. (the “Company”) is pleased to |
|
| August 12, 2024 |
Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| August 12, 2024 |
Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal |
|
| August 9, 2024 |
Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds Exhibit 99.1 Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds RAMAT GAN, Israel, Aug. 8, 2024 (GLOBE NEWSWIRE) - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced the entry into a definitive agreement |
|
| July 29, 2024 |
Exhibit 99.1 Can-Fite Provides Namodenoson Patent Update Broad Protection of Namodenoson is expected till at least 2044 PETACH TIKVA, Israel, July 29, 2024 (GLOBE NEWSWIRE) - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced an update related |
|
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal e |
|
| July 11, 2024 |
Exhibit 99.1 Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer PETACH TIKVA, Israel, July 11, 2024 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it has submitted an application |
|
| July 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal e |
|
| July 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal e |
|
| July 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal e |
|
| July 1, 2024 |
Exhibit 99.1 Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson Liver cirrhosis treatment global market is estimated to reach $29.2 billion by 2030 Ramat Gan, Israel, July 1st, 2024 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address oncological and inflammatory |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal e |
|
| June 28, 2024 |
1,219,418,700 Ordinary Shares represented by 4,064,729 American Depositary Shares Filed Pursuant to Rule 424(b)(7) Registration No. 333-276000 PROSPECTUS SUPPLEMENT NO. 1 (To Prospectus dated January 5, 2024) 1,219,418,700 Ordinary Shares represented by 4,064,729 American Depositary Shares This prospectus supplement, or the Supplement, modifies, supersedes and supplements certain information contained in, and should be read in conjunction with, that certain prospectus originall |
|
| June 28, 2024 |
Exhibit 99.1 Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix The canine osteoarthritis market is projected to reach $3 billion by 2028 Ramat Gan, Israel, June 28, 2024 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflamm |
|
| June 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal e |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal e |
|
| June 24, 2024 |
Exhibit 99.1 Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver PETACH TIKVA, Israel, June 24, 2024 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announces that company scientists cam |
|
| June 10, 2024 |
Exhibit 99.1 Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study Namodenoson showed efficacy in pre-clinical models via a definitive molecular mechanism of action PETACH TIKVA, Israel, June 10, 2024 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs th |
|
| June 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal e |
|
| June 7, 2024 |
Exhibit 99.2 CAN-FITE BIOPHARMA LTD. PROXY FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 26, 2024 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. The undersigned hereby appoints Dr. Pnina Fishman, Chairman of the Board and Motti Farbstein, Chief Executive Officer and each of them, attorneys, agents and proxies of the undersigned, with full power of substitution to |
|
| June 7, 2024 |
Exhibit 99.3 |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 495177 |
|
| June 7, 2024 |
NOTICE OF 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON June 26, 2024 Exhibit 99.1 NOTICE OF 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON June 26, 2024 To the shareholders of Can-Fite BioPharma Ltd.: Notice is hereby given that the 2024 Annual General Meeting of Shareholders will be held on Wednesday, June 26, 2024, at 3:00 p.m. Israel time at our offices, 26 Ben Gurion Street, Ramat Gan 5257346 Israel. The agenda of the annual meeting will be as follow |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal e |
|
| June 5, 2024 |
Exhibit 99.1 Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study Namodenoson granted Orphan Drug and Fast track status from the FDA RAMAT GAN, Israel, June 05, 2024 – Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced an update |
|
| May 29, 2024 |
Exhibit 99.1 Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases Ramat-Gan, Israel, May 29, 2024 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today reported that the Internati |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal ex |
|
| May 22, 2024 |
Exhibit 99.3 |
|
| May 22, 2024 |
NOTICE OF 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON June 26, 2024 Exhibit 99.1 NOTICE OF 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON June 26, 2024 To the shareholders of Can-Fite BioPharma Ltd.: Notice is hereby given that the 2024 Annual General Meeting of Shareholders will be held on Wednesday, June 26, 2024, at 3:00 p.m. Israel time at our offices, 26 Ben Gurion Street, Ramat Gan 5257346 Israel. The agenda of the annual meeting will be as follow |
|
| May 22, 2024 |
Exhibit 99.2 CAN-FITE BIOPHARMA LTD. PROXY FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 26, 2024 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. The undersigned hereby appoints Dr. Pnina Fishman, Chairman of the Board and Motti Farbstein, Chief Executive Officer and each of them, attorneys, agents and proxies of the undersigned, with full power of substitution to |
|
| May 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 4951778, |
|
| May 13, 2024 |
Exhibit 99.1 Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study Can-Fite has received agreement from both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) on the current pivotal Phase 3 clinical study RAMAT GAN, Israel, May 13, 202 |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal ex |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal ex |
|
| May 9, 2024 |
Can-Fite: FDA grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study Exhibit 99.1 Can-Fite: FDA grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study RAMAT GAN, Israel, May 09, 2024 – Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announces that the U.S. Food and Drug Administration (FDA) h |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal ex |
|
| May 6, 2024 |
Exhibit 99.1 Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602 Patent has already been issued in other major markets including the U.S. PETACH TIKVA, Israel, May 06, 2024 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address o |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of April 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal |
|
| April 25, 2024 |
Exhibit 99.1 Long-term Complete Response to Can-Fite’s Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal PETACH TIKVA, Israel, April 25, 2024 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announc |
|
| April 15, 2024 |
Exhibit 99.1 Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH A pivotal Phase III trial for advanced liver cancer, approved by FDA & EMA and a MASH Phase IIb are enrolling patients PETACH TIKVA, Israel, April 15, 2024 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancin |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of April 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal |
|
| April 5, 2024 |
Registration No. 333-259085 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 6 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Can-Fite BioPharma Ltd. (Exact name of registrant as specified in its charter) State of Israel 2834 Not applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Indus |
|
| April 5, 2024 |
Exhibit 107 Form S-8 (Form Type) Can-Fite BioPharma Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, no par value(3) Rule 457(c) and Rule |
|
| April 5, 2024 |
As filed with the Securities and Exchange Commission on April 5, 2024 As filed with the Securities and Exchange Commission on April 5, 2024 Registration No. |
|
| April 3, 2024 |
Exhibit 99.1 Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients ● Namodenoson demonstrated anti-fibrosis, anti-steatosis and anti-inflammatory effects in former Phase IIa study ● Patient enrolment for Phase IIb study is ongoing in Europe and Israel RAMAT GAN, Israel, April 3, 2024 – Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:C |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of April 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal |
|
| March 28, 2024 |
Can-Fite BioPharma Ltd. Executive Officer Clawback Policy Exhibit 97.1 Can-Fite BioPharma Ltd. Executive Officer Clawback Policy I. Purpose This Executive Officer Clawback Policy describes the circumstances under which Covered Persons of Can-Fite BioPharma Ltd. and any of its direct or indirect subsidiaries (the “Company”) will be required to repay or return Erroneously-Awarded Compensation to the Company. This Policy and any terms used in this Policy sh |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of March 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 26 Ben Gurion Street Ramat Gan 5257346 Israel (Address of principal |
|
| March 28, 2024 |
Exhibit 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Can-Fite BioPharma Ltd. (the “Company”) hereby certifies to such officer’s knowledge that: (i) the accompanying Annua |
|
| March 28, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the following Registration Statements: 1. Registration Statement (Form F-3 No. 333-236064) of Can-Fite Biopharma Ltd., 2. Registration Statement (Form F-3 No. 333-276000) of Can-Fite Biopharma Ltd., 3. Registration Statement (Form F-3 No. 333-274316) of Can-Fite Biopharma Ltd., 4. |
|
| March 28, 2024 |
Exhibit 12.1 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECURITIES EXCHANGE ACT OF 1934 RULES 13A-14(A) AND 15D-14(A), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Motti Farbstein, certify that: 1. I have reviewed this annual report on Form 20-F of Can-Fite BioPharma Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a mate |
|
| March 28, 2024 |
Exhibit 99.1 Can-Fite Reports 2023 Financial Results and Clinical Update Ewopharma acquired marketing rights for namodenoson in the treatment of pancreatic carcinoma RAMAT GAN, Israel, March 28, 2024 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today |
|
| March 28, 2024 |
Can-Fite BioPharma, Ltd. 2023 Option Plan Exhibit 4.9 Can-Fite BioPharma, Ltd. 2023 Option Plan 1. Name. This plan, as adopted by the Board of Directors of Can-Fite BioPharma, Ltd., (the “Company”) on August 30, 2023, and as amended from time to time, shall be known as the “Can-Fite BioPharma, Ltd. 2023 Option Plan” (the “Plan”). 2. Purpose of the Plan. The purposes of this Plan are to attract and retain the best available individuals for |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O |
|
| March 28, 2024 |
DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Exhibit 2.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT General Can-Fite BioPharma Ltd. is currently authorized to issue 5,000,000,000 ordinary shares, no par value. NYSE American On November 19, 2013, our ADSs began trading on the NYSE American under the symbol “CANF.” Memorandum and Articles of Association Our number with the Israeli Registrar of Companies is 512022 |
|
| March 11, 2024 |
Exhibit 99.1 Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference PETACH TIKVA, Israel, March 11, 2024 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology and inflammatory diseases, t |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of March 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 4951778 |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of February 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 4951 |
|
| February 28, 2024 |
Exhibit 99.1 Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada Patent has already been issued in other major markets including the U.S., EU, Japan and China PETACH TIKVA, Israel, February 28, 2024 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that addr |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of January 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 49517 |
|
| January 30, 2024 |
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication Exhibit 99.1 Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication PETACH TIKVA, Israel, January 30, 2024 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it has expanded its out licensing |
|
| January 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of January 2024 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 49517 |
|
| January 29, 2024 |
Exhibit 99.1 Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study Piclidenoson is a small molecule safe oral drug suitable for the chronic treatment of patients who suffer from moderate to severe plaque psoriasis PETACH TIKVA, Israel, January 29, 2024 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a p |
|
| January 3, 2024 |
Can-Fite BioPharma Ltd. 26 Ben Gurion Street Ramat Gan 5257346 Israel Can-Fite BioPharma Ltd. 26 Ben Gurion Street Ramat Gan 5257346 Israel January 3, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Can-Fite BioPharma Ltd. (CIK 0001536196) Registration Statement No. 333-276000 on Form F-3 (the “Registration Statement”) Ladies and Gentlemen: Can-Fite BioPharma Ltd. (the “Registrant”) hereby |
|
| December 28, 2023 |
As filed with the Securities and Exchange Commission on December 28, 2023 As filed with the Securities and Exchange Commission on December 28, 2023 Registration No. |
|
| December 20, 2023 |
Exhibit 99.1 The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies Robust support for Namodenoson’s potential development as an anti-obesity drug, a projected $100 billion market by 2030 PETACH TIKVA, Israel, December 20, 2023 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of pr |
|
| December 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December 2023 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 4951 |
|
| December 18, 2023 |
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan Exhibit 99.1 Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan ● FDA encouraged the Company to accelerate enrollment of adolescent patients due to Piclidenoson’s good safety profile ● There is an unmet need for safe, convenient, and effective drugs to treat chronic plaque psoriasis in children PETACH TIKVA, Israel, December 18, 2023 - Can-Fite BioPharma Ltd. (NYSE American: CANF) |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December 2023 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 4951 |
|
| December 12, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form F-3 (Form Type) Can-Fite BioPharma Ltd. |
|
| December 12, 2023 |
As filed with the Securities and Exchange Commission on December 12, 2023 As filed with the Securities and Exchange Commission on December 12, 2023 Registration No. |
|
| December 4, 2023 |
Exhibit 99.1 Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development Study will aim to enroll about 20 patients to establish safety and clinical activity PETACH TIKVA, Israel, December 4, 2023 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address on |
|
| December 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of December 2023 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 4951 |
|
| November 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2023 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 4951 |
|
| November 30, 2023 |
Exhibit 99.1 Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update Advanced liver cancer patient in prior Phase II study remains cancer-free 6.9 years after starting treatment with Namodenoson PETACH TIKVA, Israel, November 30, 2023 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that |
|
| November 22, 2023 |
Exhibit 10.1 Can-Fite Biopharma Ltd. November 21, 2023 Holder of Warrants to Purchase Ordinary Shares Represented by American Depositary Shares Issued in January 2023 and December 2021 Re: Inducement Offer to Exercise Warrant to Purchase Ordinary Shares Represented by American Depositary Shares Issued in January 2023 and December 2021 Dear Holder: Can-Fite Biopharma Ltd. (the “Company”) is pleased |
|
| November 22, 2023 |
Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| November 22, 2023 |
Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| November 22, 2023 |
846,818,700 Ordinary Shares represented by 2,822,729 American Depositary Shares Filed Pursuant to Rule 424(b)(3) Registration No. 333-269485 PROSPECTUS SUPPLEMENT (To Prospectus dated February 10, 2023) 846,818,700 Ordinary Shares represented by 2,822,729 American Depositary Shares This prospectus supplement, or the Supplement, modifies, supersedes and supplements certain information contained in, and should be read in conjunction with, that certain prospectus originally file |
|
| November 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2023 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 4951 |
|
| November 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2023 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 4951 |
|
| November 21, 2023 |
Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds Exhibit 99.1 Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds PETACH TIKVA, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced the entry into a definitive agreem |
|
| November 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2023 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 4951 |
|
| November 21, 2023 |
Exhibit 99.1 Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson PETACH TIKVA, Israel, November 22, 2023 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that a patie |
|
| November 1, 2023 |
Exhibit 99.1 Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track Company management updates about ongoing activities and progress PETACH TIKVA, Israel, November 01, 2023 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of November 2023 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 4951 |
|
| October 30, 2023 |
Exhibit 99.1 Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action ● These data support namodenoson as a leading drug candidate to treat patients in an exploratory Phase II clinical study PETACH TIKVA, Israel-(BUSINESS WIRE)-Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology co |
|
| October 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of October 2023 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 49517 |
|
| October 26, 2023 |
Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs Exhibit 99.1 Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs ● Can-Fite signed an agreement with Collaborations Pharmaceuticals, a leading expert in Artificial Intelligence and Machine Learning PETACH TIKVA, Israel, October 26, 2023 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of October 2023 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 49517 |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of October 2023 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 49517 |
|
| October 10, 2023 |
Exhibit 99.1 Can Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companies PETACH TIKVA, Israel, October 09, 2023 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology, inflammatory and liver diseases, today announced that the Company’s Direc |
|
| September 27, 2023 |
Exhibit 99.1 Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR) ● Namodenoson robustly inhibits pancreatic carcinoma growth in pre-clinical studies, via inhibition of KRAS and Wnt pathways ● Poster summarizing the inhibitory effect of Namodenoson in pancreatic carcinoma is presented today at |
|
| September 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2023 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 495 |
|
| September 11, 2023 |
Can-Fite BioPharma Ltd. 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 4951778, Israe Can-Fite BioPharma Ltd. 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 4951778, Israe September 11, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Can-Fite BioPharma Ltd. (CIK 000 1536196) Registration Statement No. 333-274316 on Form F-3 (the “Registration Statement”) Ladies and Gentlemen: Can-Fite BioPha |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2023 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 495 |
|
| September 7, 2023 |
Exhibit 99.1 Small Molecules for Big Clinical Needs NYSE American:CANF | September 2023 Investor Presentation TM Forward Looking Statement 2 This presentation contains forward - looking statements, about Can - Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects . All |
|
| September 1, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) Can-Fite BioPharma Ltd. |
|
| September 1, 2023 |
As filed with the Securities and Exchange Commission on September 1, 2023 As filed with the Securities and Exchange Commission on September 1, 2023 Registration No. |
|
| September 1, 2023 |
Registration No. 333-259085 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 5 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Can-Fite BioPharma Ltd. (Exact name of registrant as specified in its charter) State of Israel 2834 Not applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Indus |
|
| August 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2023 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 495177 |
|
| August 31, 2023 |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Exhibit 99.1 OPERATING AND FINANCIAL REVIEW AND PROSPECTS You should read the following selected financial data and discussion of our operating and financial condition and prospects in conjunction with the financial statements and the notes thereto included elsewhere in this 6-K. Our financial statements are prepared in accordance with U.S. GAAP, and reported in U.S. dollars. We maintain our accou |
|
| August 31, 2023 |
Exhibit 99.2 CAN-FITE BIOPHARMA LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2023 UNAUDITED IN U.S. DOLLARS INDEX Page Condensed Consolidated Balance Sheets 2 - 3 Condensed Consolidated Statements of Comprehensive Loss 4 Condensed Consolidated Statements of Changes in Equity 5 Condensed Consolidated Statements of Cash Flows 6 - 7 Notes to Condensed Consolidated Financial Stateme |
|
| August 31, 2023 |
Exhibit 99.3 Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies PETACH TIKVA, Israel, August 31, 2023 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology, inflammatory and liver diseases, today announced financial results for the |
|
| August 24, 2023 |
Exhibit 99.1 Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome ● Can-Fite Signed agreement with Fondazione Telethon for co-development of Piclidenoson for the treatment of Lowe syndrome an estimated $100 M market in the U.S. only with no drug available ● FDA |
|
| August 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2023 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 495177 |
|
| August 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2023 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 495177 |
|
| August 18, 2023 |
Exhibit 99.1 Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis ● FDA encouraged the Company to enroll adolescent patients due to Piclidenoson’s good safety profile ● There is an unmet need for safe, convenient, and effective drugs to treat chronic plaque psoriasis in the adolescents PETACH TIKVA, Israel, August 18, 2023 |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2023 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 495177 |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2023 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 4951778, |
|
| July 17, 2023 |
Exhibit 99.1 Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation ● Can-Fite’s novel approach for the treatment of advanced liver cancer will be presented at the American Society of Clinical Oncology (ASCO) Breakthrough Meeting in Japan on August 4th 2023 ● Namodenoson is in pivotal Phase 3 study for the treatment of |
|
| July 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of July 2023 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 4951778, |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2023 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 4951778, |
|
| June 29, 2023 |
Can-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan Exhibit 99.1 Can-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan ● FDA encouraged the Company to enroll adolescent patients due to the strong safety profile of the drug demonstrated over the development history and prior clinical studies PETACH TIKVA, Israel, June 29, 2023 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing |
|
| June 23, 2023 |
Exhibit 99.3 |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2023 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 4951778, |
|
| June 23, 2023 |
NOTICE OF 2023 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 31, 2023 Exhibit 99.1 NOTICE OF 2023 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 31, 2023 To the shareholders of Can-Fite BioPharma Ltd.: Notice is hereby given that the 2023 Annual General Meeting of Shareholders will be held on Monday, July 31, 2023, at 3:00 p.m. Israel time at our offices, 10 Bareket Street, Petach Tikva, Israel. The agenda of the annual meeting will be as follows: 1. To r |
|
| June 23, 2023 |
Exhibit 99.2 CAN-FITE BIOPHARMA LTD. PROXY FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 31, 2023 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. The undersigned hereby appoints Ilan Cohen, Chairman of the Board and Dr. Pnina Fishman, Chief Executive Officer and each of them, attorneys, agents and proxies of the undersigned, with full power of substitution to each |
|
| June 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2023 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 4951778, |
|
| June 13, 2023 |
Exhibit 99.1 Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson Namodenoson’s robust effect reached 90% inhibition of pancreatic cancer growth in pre-clinical studies PETACH TIKVA, Israel, June 13, 2023 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address onco |
|
| June 1, 2023 |
6-K 1 ea179567-6kcanfitebio.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2023 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 B |
|
| June 1, 2023 |
Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update Exhibit 99.1 Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update PETACH TIKVA, Israel, June 1, 2023 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology, inflammatory and liver diseases, today announced financial results for the three months ended March 31, 2 |
|
| May 30, 2023 |
Exhibit 99.1 Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO) ● Abstract published online in the Journal of Clinical Oncology supplement of the 2023 ASCO Annual Meeting Proceedings ● Can-Fite to initiate Phase 2a pancreatic cancer study ● Namodenoson significantly inhibits growth of pancreatic carcinoma as a stand |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2023 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 4951778, |
|
| May 9, 2023 |
Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients Exhibit 99.1 Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients ● Exploratory, small, open-label study aims to assess potential efficacy of Namodenoson following strong preclinical results in pancreatic cancer ● Namodenoson, now in a pivotal Phase 3 liver cancer study, has completely cleared liver cancer in a patient who remains cancer-free 6 years after |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2023 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 4951778, |
|
| May 2, 2023 |
Exhibit 99.1 Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists ● The anti-cancer effect in pancreatic carcinoma is mediated via a key signal transduction pathway ● According to the American Society of Clinical Oncology (ASCO) in 2020 an estimated 496,000 people were diagnosed with pancreatic cancer globally PETACH TIKVA, Israel, May 2, |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2023 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 4951778, |
|
| April 24, 2023 |
Exhibit 99.1 Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization ● Dr. Pnina Fishman appointed Executive Chairman of the Board ● Motti Farbstein appointed Chief Executive Officer in addition to continuing as Chief Financial Officer PETACH TIKVA, Israel, April 24, 2023 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology com |
|
| April 24, 2023 |
6-K 1 ea177339-6kcanfitebio.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of April 2023 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 |
|
| April 21, 2023 |
Exhibit 107 Form S-8 (Form Type) Can-Fite BioPharma Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, no par value (3) Rule 457(c) 25,692,0 |
|
| April 21, 2023 |
As filed with the Securities and Exchange Commission on April 21, 2023 As filed with the Securities and Exchange Commission on April 21, 2023 Registration No. |
|
| April 21, 2023 |
Registration No. 333-259085 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 4 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Can-Fite BioPharma Ltd. (Exact name of registrant as specified in its charter) State of Israel 2834 Not applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Indus |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of April 2023 001-36203 (Commission File Number) CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 4951778 |
|
| April 10, 2023 |
Exhibit 99.1 Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment The Pivotal Study is Aimed to Support a Marketing Authorization Application PETACH TIKVA, Israel, April 10, 2023 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory |
|
| March 31, 2023 |
Power of Attorney (included in signature page)** Registration No. 333-259085 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 3 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Can-Fite BioPharma Ltd. (Exact name of registrant as specified in its charter) State of Israel 2834 Not applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Indus |
|
| March 30, 2023 |
Certification by Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002* Exhibit 12.1 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT I, Pnina Fishman, certify that: 1. I have reviewed this annual report on Form 20-F of Can-Fite BioPharma Ltd; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circu |
